Latest in Alzheimer’s Be
Sort by
11 items
-
Chancellor and BoE governor call for UK to rebuild ties with EU
Reeves and Bailey highlight damage from Brexit amid concern about Trump’s plan to impose tariffs on trading partnersBusiness - Financial Times - November 14 -
Britain’s bold plan to create super funds
The case for consolidating the UK’s sprawling pension arsenal is strongBusiness - Financial Times - November 14 -
Are cancer survivors less likely to develop Alzheimer’s?
Research shows that patients with a history of cancer are less likely to develop dementia and those with Alzheimer’s are less likely to develop cancer. Understanding this relationship, say ...World - The Guardian - November 16 -
Alzheimer’s Can Be a World of Endless Second Chances
When Dad first started forgetting things, I thought I’d lost him. I didn’t imagine I’d have more of him than I did before.Top stories - The New York Times - 3 hours ago -
Alzheimer's researchers say brain stimulation device may slow symptoms
Alzheimer's disease researchers found that when they aimed a TMS device at the right spot in the brain, it could slow the progression of memory loss.Top stories - NBC News - November 1 -
Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results
Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.Business - The New York Times - 3 days ago -
Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results
Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.Health - The New York Times - 3 days ago -
Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese partner Eisai — reversing ...Business - MarketWatch - November 14 -
European committee takes a second look at Alzheimer's drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drugHealth - ABC News - November 14 -
Cassava Sciences’ stock craters after Alzheimer’s disease trial fails to meet its goals
The biotech company said it will discontinue a second trial but will still offer a full analysis of the data.Business - MarketWatch - 4 days ago -
‘We’re living in uncertainty’: My sister has Alzheimer’s disease. How do I know the right time to take control of her finances?
“My eldest sister has asked me to take on her power of attorney for her, and together we met with her attorney.”Business - MarketWatch - 4 days ago